Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against BioAge Labs, Inc. due to a class action complaint related to the company's IPO and alleged breaches of fiduciary duties by its board of directors [1] Group 1: Legal Investigation - A class action complaint was filed against BioAge on January 7, 2024, concerning its registration statement for the IPO held on September 26, 2024 [1] - The investigation focuses on whether BioAge's board of directors has breached their fiduciary duties to the company [1] Group 2: Product and Market Impact - On December 6, 2024, BioAge announced the discontinuation of the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety concerns related to elevated liver transaminase levels [2] - This announcement was unexpected, as BioAge had previously highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs during its IPO [2] Group 3: Stock Price Reaction - Following the announcement regarding the discontinuation of the trial, BioAge's stock price fell significantly from $20.09 per share on December 6, 2024, to $4.65 per share on December 7, 2024 [3]

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into CareDx, Inc. for potential breaches of fiduciary duties and violations of federal securities laws [1][2]. Investigation Details - The investigation focuses on actions taken by CareDx insiders between April 30, 2020, and February 24, 2022, which involved issuing false and misleading statements about the company's compliance with healthcare laws and revenue growth [2]. - CareDx began disclosing issues on October 28, 2021, revealing that the company was under multiple government investigations and that its financial results were significantly lower than previously reported [2]. - By November 3, 2022, CareDx's share price had decreased by over 77.22% from its previous levels [2]. Shareholder Information - Current stockholders who have held CareDx stock since at least January 2021 are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3].

Core Viewpoint - The Board of Directors of Victoria's Secret & Co. has adopted a limited-duration shareholder rights plan to protect the interests of all shareholders in response to significant stock accumulation by BBRC International Pte Limited [2][3][4] Group 1: Rights Plan Details - The Rights Plan is effective immediately and will expire in one year, specifically on May 18, 2026 [2][8] - Each shareholder will receive one right for each share of common stock as of May 29, 2025, which will initially trade with the common stock [5][8] - The rights become exercisable if any person acquires 15% or more of the outstanding common stock, or 20% for certain passive investors [5][6] Group 2: Rationale for the Rights Plan - The Board adopted the Rights Plan due to the substantial accumulation of shares by BBRC, which began increasing its position to approximately 13% starting in March 2025 [3][6] - The Board expressed concerns about the current market dislocation in the retail sector and its impact on the trading value of the Company's shares, which they believe does not reflect the inherent value of VS&Co [3][4] - The Rights Plan aims to ensure fair treatment of all shareholders in the event of a takeover and to prevent control from being gained without appropriate compensation [4][6] Group 3: Engagement with BBRC - The Company has maintained open dialogue with BBRC and values their investment, indicating a willingness to continue discussions [4] - BBRC has a history of acquiring controlling interests in retail companies and has recently launched a new global lingerie and beauty brand [6][4] Group 4: Company Overview - Victoria's Secret & Co. is a specialty retailer known for its fashion-inspired collections, including lingerie, sleepwear, and beauty products, with a global presence of approximately 1,380 retail stores in nearly 70 countries [9]

Group 1 - A class action has been filed against Krispy Kreme, Inc. for allegedly misleading investors regarding its partnership with McDonald's [1] - The complaint claims that demand for Krispy Kreme products at McDonald's locations declined significantly after the initial marketing launch, impacting average sales [1] - Krispy Kreme reported a net revenue of $375.2 million for Q1 2025, a decline of 15.3%, and a net loss of $33.4 million compared to a net loss of $6.7 million in the prior year [2] Group 2 - The company announced it is reassessing its deployment schedule with McDonald's and has withdrawn its prior full-year outlook due to uncertainty around the partnership [2] - Following the financial results announcement, Krispy Kreme's share price fell by nearly 25%, negatively affecting investors [2] - Shareholders interested in participating in the class action must file their papers by July 15, 2025, to serve as lead plaintiff [3]

Core Viewpoint - The proposed buyout of TaskUs, Inc. by its three largest shareholders, including Blackstone, is under investigation due to concerns about the fairness of the deal and potential conflicts of interest [1][4]. Company Overview - TaskUs is recognized as a leading provider of outsourced digital services and next-generation customer experience for innovative companies [2]. - The company has a positive outlook, with Wall Street analysts setting an average one-year stock price target of $18.50 per share, and a high target of $22 per share [2]. Buyout Details - On May 9, 2025, TaskUs announced its sale to a buyer group that already holds a majority of the company's voting power, with the buyout price set at $16.50 per share for public shareholders [3]. - The buyout is being pursued by Blackstone and co-founders Bryce Maddock and Jaspar Weir, who will continue their roles in the company post-acquisition [3][4]. Legal Investigation - Julie & Holleman LLP is investigating the buyout for potential legal claims, citing concerns over the deal's fairness and the low buyout price compared to the company's true value [1][4].

Core Viewpoint - Julie & Holleman LLP is investigating potential claims against Iovance Biotherapeutics, Inc. and its executives due to recent losses suffered by the company's stockholders [1][2]. Group 1: Legal Investigation - A complaint filed in federal court alleges that Iovance and its executives misled investors by exaggerating the company's financial prospects and downplaying risk factors affecting growth potential [2]. - The complaint specifically claims that the company concealed its inability to generate demand and was ill-equipped to capitalize on existing demand for its treatments through its network of approved treatment centers [2]. Group 2: Firm Background - Julie & Holleman LLP is a boutique law firm specializing in shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations [4]. - The firm's attorneys have a track record of securing hundreds of millions of dollars for aggrieved companies and their shareholders [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edison International due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1] Group 1: Allegations and Claims - The class action complaint alleges that Edison made false and misleading statements regarding its Public Safety Power Shutoffs program, claiming it was used to mitigate wildfire risks, which was found to be false [2] - The complaint states that the misleading claims resulted in increased fire risk in California and heightened legal exposure for Edison [2] - As a result of these misleading statements, the lawsuit claims that investors suffered damages when the true information became public [2] Group 2: Legal Representation - Bragar Eagel & Squire, P.C. is representing long-term stockholders of Edison and is seeking information related to the claims [3] - The firm emphasizes that there is no cost or obligation for stockholders to inquire about their rights or interests regarding these matters [3] Group 3: Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with expertise in representing individual and institutional investors in complex litigation [4] - The firm operates in both New York and California, handling cases in state and federal courts across the country [4]

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ModivCare, Inc. (NASDAQ: MODV) on behalf of long-term stockholders following a class action complaint that was filed against ModivCare on January 29, 2025 with a Class Period from November 3, 2022, to September 15, 2024. Our investigation concerns whether the board of directors of ModivCare have breached their fiduciary duties to the company. ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Kyverna Therapeutics, Inc. due to a class action complaint alleging that the company made false and misleading statements regarding its IPO and clinical data [1][2] Group 1: Legal Investigation - The investigation is focused on whether Kyverna's board of directors breached their fiduciary duties to the company [1] - A class action complaint was filed on December 9, 2024, related to the company's IPO conducted on February 8, 2024 [1] Group 2: Allegations of Misleading Information - The complaint states that Kyverna possessed adverse data related to one of its ongoing trials, which was not disclosed [2] - The undisclosed adverse data negatively impacted the company's lead product, making the trends and results in the offering documents misleading [2] - The company's discussion of risk factors was inadequate, failing to describe the risks associated with withholding clinical data [2] Group 3: Investor Impact - Investors suffered damages when the market learned the truth about Kyverna's misleading public statements [2]

HALIFAX, Nova Scotia, May 15, 2025 (GLOBE NEWSWIRE) -- Morien Resources Corp. ("Morien" or the "Company") (TSX-V:MOX) is pleased to announce its shareholders voted in favour of all items of business brought before them at the Company's Annual and Special Meeting of Shareholders (“AGM”) held in Halifax on May 14, 2025. Election of Directors The number of directors was set by the Board at four, with John Budreski, Dawson Brisco, Mary Ritchie, and Beau White re-elected to the Company's Board for the ensuing y ...